Manulife (Manufacturers Life Insurance)
TCRR

Manulife (Manufacturers Life Insurance)’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,653
Closed -$68 – 3220
2021
Q4 		$68 Sell
14,653
-5,749
-28% -$35.9K ﹤0.01% 3081
2021
Q3 		$174K Buy
20,402
+1,915
+10% +$27.1K ﹤0.01% 3030
2021
Q2 		$303K Buy
18,487
+1,356
+8% +$27.4K ﹤0.01% 2804
2021
Q1 		$378K Buy
17,131
+1,526
+10% +$41.6K ﹤0.01% 2464
2020
Q4 		$483K Buy
15,605
+1,002
+7% +$25.3K ﹤0.01% 2220
2020
Q3 		$297K Buy
14,603
+3,959
+37% +$69.5K ﹤0.01% 2304
2020
Q2 		$166K Buy
+10,644
New +$123K ﹤0.01% 2580

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s TCRR Position: Q1 2022 in Review

Manulife (Manufacturers Life Insurance) sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2022, closing a stake of 14,653 shares — an estimated $68 sold.

Manulife (Manufacturers Life Insurance) first reported a position in TCRR in Q2 2020 and held it in 7 quarters. The position peaked at $483K in Q4 2020. 94 funds tracked by Wall St. Rank hold TCRR as of Q1 2022.

  • Manulife (Manufacturers Life Insurance) reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 14,653 TCR2 Therapeutics Inc. Common Stock shares in Q1 2022, an estimated $68.
  • Manulife (Manufacturers Life Insurance) first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2020 and held it in 7 quarters.
  • Manulife (Manufacturers Life Insurance)'s TCR2 Therapeutics Inc. Common Stock position peaked at $483K in Q4 2020.
  • 94 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2022.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2022, filed 20 May 2022.